Note:
■Forward-looking statements, such as business forecasts, made in these financial statements are based on managements'
estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc.
that they will be achieved. A number of factors could cause actual results to differ materially from expectations.
-Unaudited figures are included in this material for reference.
-Yen amounts presented in these materials are rounded to the nearest hundred million for amounts in billions and truncated for amounts in millions,

- In these materials, "-" indicates that an amount has not been recognized, and " 0 " indicates a fractional amount due to rounding.

1. Financial Statement Overview
<Based on accounting policies applied from FY2014 >


| < Based on former accounting policies > |  |
| :---: | :---: |
| (1) Operating Results |  |
| Net Sales* | M. JPY |
| Gross profit | M. JPY |
| Operating income | M. JPY |
| Ordinary profit | M. JPY |
| Net income | M. JPY |
| Earnings per share | JPY |
| Return on equity (ROE) |  |
| Ratio of net income to total assets |  |
| Ratio of operating income to net sales |  |
| Ratio of ordinary income to net sales |  |
| (2) Statement of Changes in Financial Position |  |
| Total assets | M. JPY |
| Net assets | M. JPY |
| Shareholders' equity | M. JPY |
| Shareholders' equity ratio |  |
| Book value per share | JPY |
| (3) Summary of Cash Flow Statement |  |
| Net cash provided by operating activities | M. JPY |
| Net cash used in investing activities | M. JPY |
| Net cash used in financing activities | M. JPY |
| Cash and cash equivalents at end of period | M. JPY |


iness and some other brisses,
(Post-reclassification basis from fiscal 2009.)

|  | FY ending Mar/15 (projected) | 6 Months ended Sept/14 | FY ended Mar/14 | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Consolidated domestic subsidiaries | 39 | 40 | 39 | 39 | 38 | 42 | 41 | 42 |
| Consolidated overseas subsidiaries | 51 | 51 | 50 | 50 | 48 | 51 | 54 | 58 |
| Sub-Total | 90 | 91 | 89 | 89 | 86 | 93 | 95 | 100 |
| Domestic affiliates subject to equity method | 6 | 6 | 6 | 6 | 5 | 4 | 4 | 4 |
| Overseas affiliates subject to equity method | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Sub-Total | 12 | 12 | 12 | 12 | 11 | 10 | 10 | 10 |
| Parent company | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 103 | 104 | 102 | 102 | 98 | 104 | 106 | 111 |


| 3. Change of Number of Consolidated Subsidiaries/Affiliates (from Mar/13 to Sept/14) |
| :--- |
| Increase(2) <br>  <br> Decrease(0)    Increase:KYODO ACE LOGISTICS CORPORATION, PT Ajinomoto Sales Indonesia <br>  Decrease: None    <br> Equity method Increase(0)    <br>  Decrease(0)    |



|  | $\begin{aligned} & \text { FY ending } \\ & \text { Mar/115 } \\ & \text { (projected) } \end{aligned}$ | 6 Months ended Sept/14 | $\begin{aligned} & \text { FY ended } \\ & \text { Mar/14 } \end{aligned}$ | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar12 | FY ended Mar/11 | FY ended Mar10 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Parent Company |  | 3,518 4.252 | 3,398 4.199 | 3,418 4 429 | 3,343 4.211 | 3,300 4.195 | 3,310 4.186 | 3,755 4175 |
| Consolidated Basis |  | 29,829 | 27,579 | 27,600 | 27,518 | 28,245 | 28,084 | 27,215 |


|  | As of Mar/15 (projected) | As of Sept/14 | As of Mar/14 | As of Sept/13 | As of Mar/13 | As of Mar/12 | As of Mar/11 | As of Mar/10 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Short-term borrowings and debt | 7 | 33,437 | 37,327 | 50,468 | 36,764 | 23,423 | 22,407 | 31,529 |
| Commercial paper |  | 15,000 | 0 | 20,000 | 0 | 0 | 0 | 0 |
| Bonds |  | 19,994 | 34,993 | 34,993 | 49,992 | 69,990 | 69,989 | 69,988 |
| Long-term debt |  | 68,705 | 70,634 | 30,877 | 32,557 | 36,626 | 40,994 | 46,384 |
|  |  | 137,137 | 142,954 | 136,338 | 119,314 | 130,040 | 133,391 | 147,902 |
| Cash and deposits with bank |  | 156,397 | 132,416 | 144,354 | 186,501 | 149,913 | 141,801 | 97,866 |
|  |  | -19,260 | 10,538 | -8,016 | -67,187 | -19,873 | -8,410 | 50,035 |


|  | FY ending Mar/15 (projected) | 6 Months ended Sept/14 | FY ended Mar/14 | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (1) Parent company | 92 | 51 | 128 | 63 | 130 | 132 | 156 | 183 |
| Subsidiaries | 362 | 162 | 334 | 164 | 304 | 315 | 356 | 376 |
| Adjustment | - | -2 | -4 | -2 | -9 | -10 | -14 | -5 |
| Total | 454 | 211 | 457 | 225 | 425 | 437 | 498 | 554 |
| (2) By business segment |  |  |  |  |  |  |  |  |
| Domestic Food Products | 91 | 39 | 96 | 47 | 103 | 129 | 137 | 150 |
| Overseas Food Products | 131 | 64 | 132 | 66 | 98 | 86 | 100 | 104 |
| Bioscience Products \& Fine Chemicals | 131 | 64 | 133 | 64 | 113 | 106 | 138 | 182 |
| Pharmaceuticals | 14 | 7 | 21 | 11 | 33 | 37 | 36 | 37 |
| Other Business | 25 | 11 | 21 | 10 | 19 | 22 | 24 | 21 |
| All Company | 61 | 26 | 54 | 27 | 58 | 58 | 64 | 60 |
| Total | 454 | 211 | 457 | 225 | 425 | 437 | 498 | 554 |

*In FY2014, the Company change its depreciation method (from the declining balance method to the straight-line method) and revise the terms of useful lives.
*Change of product classification: Medical \& Functional foods in Pharmaceuticals
: from Pharmaceuticals to Other Business since FY ended Mar/14.
(Figures for previous periods have not been restated to reflect segment changes.)


[^0](Figures for previous periods have not been restated to reflect segment changes.)

|  | FY ending Mar/15 (projected) | 6 Months ended Sept/14 | $\begin{gathered} \text { FY ended } \\ \text { Mar/14 } \\ \hline \end{gathered}$ | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (1) Parent company | 264 | 102 | 241 | 122 | 239 | 245 | 270 | 298 |
| Subsidiaries | 79 | 47 | 77 | 37 | 87 | 104 | 99 | 59 |
|  | 343 | 148 | 319 | 159 | 326 | 348 | 369 | 356 |
| (2) By business segment |  |  |  |  |  |  |  |  |
| Domestic Food Products | 35 | 17 | 29 | 14 | 37 | 47 | 60 | 64 |
| Overseas Food Products | 34 | 15 | 28 | 14 | 28 | 30 | 28 | 22 |
| Bioscience Products \& Fine Chemicals | 77 | 37 | 75 | 37 | 76 | 76 | 87 | 100 |
| Pharmaceuticals | 67 | 28 | 81 | 40 | 95 | 114 | 112 | 97 |
| Other Business | 8 | 4 | 7 | 3 | 7 | 8 | 12 | 0 |
| All Company | 122 | 46 | 97 | 51 | 84 | 73 | 72 | 73 |
|  | 343 | 148 | 319 | 159 | 326 | 348 | 369 | 356 |

*Change of product classification: Medical \& Functional foods in Pharmaceuticals
(Figures for previous periods have not been restated to reflect segment in each fiscal year
10. Selling, G\&A Expenses

|  | $\begin{gathered} \hline \text { FY ending } \\ \text { Mar/15 } \\ \text { (projected) } \\ \hline \end{gathered}$ | 6 Months ended Sept/14 | $\begin{gathered} \text { FY ended } \\ \text { Mar/14 } \\ \hline \end{gathered}$ | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (1) Selling Expense |  |  |  |  |  |  |
| Transportation | , | 17,443 | 31,143 | 15,214 | 32,231 | 35,538 |
| Advertisement | / | 11,039 | 21,421 | 10,348 | 22,322 | 22,007 |
| Sales commission | - | 10,377 | 24,316 | 11,181 | 39,890 | 50,013 |
| Miscellaneous |  | 651 | 1,273 | 702 | 1,259 | 1,068 |
| Total |  | 39,512 | 78,155 | 37,446 | 95,703 | 108,627 |
| (2) General and Administrative Expenses |  |  |  |  |  |  |
| Salaries |  | 23,412 | 43,989 | 22,313 | 43,955 | 45,238 |
| Bonuses and other allowances |  | 9,133 | 17,097 | 8,601 | 17,421 | 18,888 |
| Periodic pension and severance cost |  | 3,824 | 5,782 | 2,542 | 6,561 | 8,971 |
| Depreciation expense |  | 4,219 | 9,687 | 4,523 | 9,948 | 10,395 |
| Amortization of goodwill* | 1,510 | 769 | 1,589 | 807 | 2,265 | 4,503 |
| Other | $\bigcirc$ | 48,461 | 97,655 | 49,289 | 100,989 | 100,021 |
| Total | - | 89,820 | 175,802 | 88,076 | 181,139 | 188,016 |
| Total Selling, G\&A expenses | 273,400 | 129,332 | 253,957 | 125,522 | 276,842 | 296,643 |

*The following accounting policies are changed from ry2014.
Sales promotion discounts paid to customers to expand sales are deducted from net sales.
Sales promotion discounts paid to customers to expand sales are dedu
(Figures for FY 2011 and subsequent fiscal years have been restated.)
*Names and definitions of items in the breakdown of sales expenses have been changed from fiscal 2014
(Figures for FY2011 and subsequent fiscal years have been restated.)

| < Based on former accounting policies > |
| :--- |
|   <br>   <br> (1) Selling Expense  <br> Transportation  <br> Advertisement  <br> Sales commission  <br> Miscellaneous  <br> (2) General and Administrative Expenses  <br> Salaries  <br> Bonuses and other allowances  <br> Periodic pension and severance cost  <br> Depreciation expense  <br> Amortization of goodwill  <br> Other  <br>   <br>   |


| $\begin{gathered} \text { FY ended } \\ \text { Mar/14 } \\ \hline \end{gathered}$ | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 29,356 | 14,356 | 31,423 | 34,265 | 33,450 | 31,675 |
| 30,330 | 14,717 | 32,700 | 32,571 | 33,628 | 34,213 |
| 40,688 | 19,246 | 53,681 | 61,331 | 62,089 | 58,560 |
| 24,433 | 11,531 | 22,552 | 22,257 | 23,809 | 23,606 |
| 124,808 | 59,853 | 140,357 | 150,425 | 152,978 | 148,055 |
| 43,989 | 22,313 | 43,955 | 45,238 | 42,981 | 42,847 |
| 17,097 | 8,601 | 17,421 | 18,888 | 17,898 | 16,938 |
| 5,782 | 2,542 | 6,561 | 8,971 | 9,484 | 8,365 |
| 9,687 | 4,523 | 9,948 | 10,395 | 10,543 | 9,583 |
| 1,589 | 807 | 2,265 | 4,503 | 4,505 | 5,000 |
| 90,235 | 45,283 | 92,594 | 92,781 | 95,211 | 90,472 |
| 168,381 | 84,070 | 172,747 | 180,777 | 180,625 | 173,208 |
| 293,190 | 143,923 | 313,104 | 331,203 | 333,604 | 321,264 |



1H-FY2014 Consolidated Results

| (1HFY2014 Consolidated Resuls |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \text { FY ending } \\ \text { Mar/15 } \\ \text { (projected) } \end{gathered}$ | 6 Months ended Sept/14 | $\begin{aligned} & \text { FY ended } \\ & \text { Mar/14 } \end{aligned}$ | 6 Months ended Sept/13 | FY ended Mar113 | FY ended Mar/12 | FY ended Mar11 | FY ended Mar/10 |
|  |  |  |  |  |  |  |  |  |
| Gain on prior period adjustment |  |  |  |  |  |  |  | 1,322 |
| Gain on sales of fixed assets |  | - | 3,081 | - |  |  | 0 |  |
| Gain on sales of investment securrities |  | - |  | - |  | 554 | 912 |  |
| Gain on sales of investments in affiliates |  | - | 2,315 | 2,267 | 18,201 | , | 0 |  |
| Reversal of accrued expense on contract alteration | - | - |  | - |  | 0 | 0 | 1,437 |
| Cancellation money |  | - | - | - | - |  | 0 |  |
| Insurance income |  | 10 | 1,189 | 1,190 | 1,800 | 6,012 | 182 |  |
| Gain on transfer of benefit obligation relating to employees' pension fund | $I$ |  |  | - | 27,752 | 0 | 0 | 0 |
| Gain on bad debts recovered |  | 581 | - 2.036 | - 250 | - ${ }^{1,837}$ | 1 | 2 |  |
| Other |  | 316 | 2,036 | 250 | 1,837 | 521 | 2,126 | 609 |
| Total |  | 908 | 8,621 | 3,708 | 49,141 | 7,088 | 3,220 | 3,368 |
|  |  |  |  |  |  |  |  |  |
|  |  | 505 | 1,222 | 662 | ${ }_{14,561}$ | 3,320 1,106 |  | 4,536 |
| Loss on sales of fixed assets | , | - | , | $\cdots$ |  |  |  | 14,325 |
| Loss on devaluation of securities |  | - | 0 | - | 2,346 | 607 | 7,416 |  |
| Retirement benefit expenses |  | - | 0 | - | , | , | 0 | 0 |
| Loss on devaluation of investments in affiliates |  |  |  | - | 0 |  | 0 |  |
| Loss on liquidation of affiliates |  | - | 859 | 702 | 0 |  | 0 | 0 |
| Loss from natural disaster |  | - |  | - | - 0 | 3,759 | 3,231 |  |
| Other |  | 838 | 2,155 | 670 | 7,966 | 2,121 | 6,123 | 7,337 |
| Total |  | 1,343 | 4,860 | 2,036 | 25,481 | 10,915 | 25,275 | 26,198 |

## 13. Information by Business segment

| Based on accounting policies applied from FY2014> (in millions of JPY) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \text { FY ending } \\ \text { Mar/15 } \\ \text { (projected) } \end{gathered}$ | 6 Months ended Sept/14 | $\begin{gathered} \text { FY ended } \\ \text { Mar/14 } \\ \hline \end{gathered}$ | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 |
| Domestic Food Products |  |  |  |  |  |  |
| Sales to external customers | 312,300 | 147,298 | 299,925 | 144,282 | 357,057 | 396,268 |
| Y/Y \% | 104\% | 102\% | 84\% |  | 90\% |  |
| Operating income | 28,800 | 10,107 | 27,056 | 11,368 | 32,641 | 31,705 |
| Y/Y \% | 106\% | 89\% | 83\% |  | 103\% |  |
| Overseas Food Products |  |  |  |  |  |  |
| Sales to external customers | 322,200 | 153,135 | 292,366 | 144,073 | 245,085 | 229,960 |
| Y/Y \% | 110\% | 106\% | 119\% | - | 107\% |  |
| Operating income | 29,400 | 16,421 | 25,042 | 12,801 | 20,703 | 21,545 |
| Y/Y \% | 117\% | 128\% | 121\% |  | 96\% |  |
| Bioscience Products \& Fine Chemicals |  |  |  |  |  |  |
| Sales to external customers | 238,400 | 108,265 | 228,102 | 111,629 | 203,801 | 197,648 |
| Y/Y \% | 105\% | 97\% | 112\% |  | 103\% |  |
| Operating income | 9,700 | 2,573 | 6,390 | 3,879 | 14,368 | 12,159 |
| Y/Y \% | 152\% | 66\% | 44\% |  | 118\% |  |
| Pharmaceuticals |  |  |  |  |  |  |
| Sales to external customers | 40,900 | 18,793 | 51,228 | 27,899 | 71,450 | 77,922 |
| Y/Y \% | 80\% | 67\% | 72\% |  | 92\% |  |
| Operating income | 2,300 | 235 | 3,811 | 1,531 | 3,194 | 6,488 |
| Y/Y \% | 60\% | 15\% | 119\% | - | 49\% |  |
| Other Business |  |  |  |  |  |  |
| Sales to external customers | 94,200 | 40,129 | 79,736 | 41,022 | 71,312 | 70,847 |
| Y/Y \% | 118\% | 98\% | 112\% |  | 101\% | - |
| Operating income | -200 | -750 | -493 | 163 | 324 | 686 |
| Y/Y \% | 41\% | - | - | - | 47\% | - |
| Consolidated, Total |  |  |  |  |  |  |
| Net Sales | 1,008,000 | 467,622 | 951,359 | 468,907 | 948,705 | 972,648 |
| Y/Y \% | 106\% | 100\% | 100\% |  | 98\% |  |
| Operating income | 70,000 | 28,588 | 61,807 | 29,744 | 71,232 | 72,584 |
| Y/Y \% | 113\% | 96\% | 87\% | - | 98\% | - |

*The following accounting policies are changed from FY2014.
Sales promotion discounts paid to customers to expand sales are deducted from net sales
Sales promotion discounts paid to customers to expand sales are deduct

| < Based on former accounting policies > |
| :--- |
| Domestic Food Products <br> Sales to external customers <br> Y/Y \% <br> Operating income <br> Y/Y \% |
| Overseas Food Products |
| Sales to external customers |
| Y/Y \% |
| Operating income |
| Y/Y \% |
| Bioscience Products \& Fine Chemicals |
| Sales to external customers |
| Y/Y \% |
| Operating income |
| Y/Y \% |
| Pharmaceuticals |
| Sales to external customers |
| Y/Y \% |
| Operating income |
| $Y / Y \%$ |


| $\begin{aligned} & \text { FY ended } \\ & \text { Mar/14 } \\ & \hline \end{aligned}$ | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{r} 337,533 \\ 86 \% \\ 27,429 \\ 84 \% \\ \hline \end{array}$ | $\begin{array}{r} 161,177 \\ 73 \% \\ 10,961 \\ 63 \% \\ \hline \end{array}$ | $\begin{array}{r} 391,554 \\ 91 \% \\ 32,641 \\ 103 \% \\ \hline \end{array}$ | $\begin{array}{r} 428,996 \\ 100 \% \\ 31,705 \\ 120 \% \\ \hline \end{array}$ | $\begin{array}{r} 427,707 \\ 100 \% \\ 26,506 \\ 109 \% \\ \hline \end{array}$ |  |
| $\begin{array}{r} 293,237 \\ 119 \% \\ 25,231 \\ 122 \% \\ \hline \end{array}$ | $\begin{array}{r} 144,501 \\ 126 \% \\ 12,877 \\ 126 \% \\ \hline \end{array}$ | $\begin{array}{r} 245,397 \\ 106 \% \\ 20,703 \\ 96 \% \\ \hline \end{array}$ | $\begin{array}{r} 230,541 \\ 99 \% \\ 21,545 \\ 80 \% \\ \hline \end{array}$ | $\begin{array}{r} 231,990 \\ 198 \% \\ 26,837 \\ 105 \% \\ \hline \end{array}$ |  |
| $\begin{array}{r} 228,528 \\ 112 \% \\ 6,530 \\ 45 \% \\ \hline \end{array}$ | $\begin{array}{r} 111,816 \\ 115 \% \\ 3,923 \\ 54 \% \\ \hline \end{array}$ | $\begin{array}{r} 204,206 \\ 103 \% \\ 14,368 \\ 118 \% \\ \hline \end{array}$ | $\begin{array}{r} 198,021 \\ 100 \% \\ 12,159 \\ 140 \% \\ \hline \end{array}$ | 198,291 $102 \%$ 8,685 $165 \%$ | 193,553 <br> 5,252 |
| $\begin{array}{r} 51,228 \\ 72 \% \\ 3,842 \\ 120 \% \\ \hline \end{array}$ | $\begin{array}{r} 27,899 \\ 78 \% \\ 1,546 \\ 86 \% \end{array}$ | $\begin{array}{r} 71,450 \\ 92 \% \\ 3,194 \\ 49 \% \\ \hline \end{array}$ | $\begin{array}{r} 77,922 \\ 94 \% \\ 6,488 \\ 82 \% \\ \hline \end{array}$ | $\begin{array}{r} 82,645 \\ 100 \% \\ 7,940 \\ 64 \% \\ \hline \end{array}$ | $82,594$ 12,353 |
| $\begin{array}{r} 80,804 \\ 112 \% \\ -485 \end{array}$ | $\begin{array}{r} 41,699 \\ 112 \% \\ 213 \\ 74 \% \\ \hline \end{array}$ | $\begin{array}{r} 72,358 \\ 101 \% \\ 324 \\ 47 \% \end{array}$ | $\begin{array}{r} 71,727 \\ 96 \% \\ 686 \end{array}$ | $\begin{array}{r} 74,579 \\ 113 \% \\ -595 \\ 18 \% \end{array}$ | 66,155 <br> $-3,347$ |
| $\begin{array}{r} 991,332 \\ 101 \% \\ 62,548 \\ 88 \% \\ \hline \end{array}$ | $\begin{array}{r} 487,084 \\ 96 \% \\ 29,521 \\ 80 \% \end{array}$ | $\begin{array}{r} 984,967 \\ 98 \% \\ 71,232 \\ 98 \% \\ \hline \end{array}$ | $\begin{array}{r} 1,007,208 \\ 99 \% \\ 72,584 \\ 105 \% \end{array}$ | $1,015,215$ $103 \%$ 69,374 $108 \%$ | 982,664 <br> 64,034 |

Change of product classification:
-Domestic Food Products: Previous years' figures for Kellogg's products

- Domestic Food Products: Previous years
restated as net sales less cost of sales.
(figures for previous years not restatedticals to Other Busines
Pharmaceuticals: Sales decreased due to transfer of Infusions and dialysis business in July 2013.

14. Information by Geographic segment

|  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & \text { FY ending } \\ & \text { Mar/15 } \\ & \text { (projected) } \\ & \hline \end{aligned}$ | 6 Months ended Sept/14 | $\begin{aligned} & \text { FY ended } \\ & \text { Mar/14 } \\ & \hline \end{aligned}$ | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 |
| Japan |  |  |  |  |  |  |
| Sales to external customers | 481,700 | 225,339 | 474,948 | 235,602 | 541,509 | 590,828 |
| Y/Y \% | 101\% | 96\% | 88\% |  | 92\% |  |
| Operating income | 30,700 | 11,882 | 32,724 | 14,155 | 34,350 | 35,555 |
| Y/Y \% | 94\% | 84\% | 95\% |  | 97\% |  |
| Asia |  |  |  |  |  |  |
| Sales to external customers | 259,300 | 120,334 | 230,269 | 115,236 | 194,533 | 177,396 |
| Y/Y \% | 113\% | 104\% | 118\% |  | 110\% |  |
| Operating income | 29,500 | 14,945 | 24,847 | 13,280 | 22,105 | 21,585 |
| Y/Y \% | 119\% | 113\% | 112\% |  | 102\% |  |
| Americas |  |  |  |  |  |  |
| Sales to external customers | 159,500 | 72,043 | 139,287 | 68,078 | 117,483 | 114,084 |
| Y/Y \% | 115\% | 106\% | 119\% |  | 103\% |  |
| Operating income | 9,400 | 3,130 | 4,197 | 2,655 | 9,285 | 8,888 |
| Y/Y \% | 224\% | 118\% | 45\% |  | 104\% |  |
| Europe |  |  |  |  |  |  |
| Sales to external customers | 107,500 | 49,904 | 106,853 | 49,990 | 95,178 | 90,338 |
| Y/Y \% | 101\% | 100\% | 112\% |  | 105\% |  |
| Operating income | 400 | -1,369 | 37 | -347 | 5,491 | 6,554 |
| Y/Y \% | 1081\% | - | 1\% | - | 84\% |  |
| Consolidated, Total |  |  |  |  |  |  |
| Sales to external customers | 1,008,000 | 467,622 | 951,359 | 468,907 | 948,705 | 972,648 |
| Y/Y \% | 106\% | 100\% | 100\% |  | 98\% |  |
| Operating income | 70,000 | 28,588 | 61,807 | 29,744 | 71,232 | 72,584 |
| Y/Y \% | 112\% | 96\% | 87\% | - | 98\% | - |

Sales promotion discounts paid to customers to expand sales are deducted from net sales. (Figures for FY2011 and subsequent fiscal years have been restated.)

| < Based on former accounting policies > |
| :--- | | Japan** |
| :--- |
| Sales to external customers |
| Y/V \% |
| Operating income |
| Y/Y \% |


| FY ended Mar/14 | 6 Months ended Sept/13 | FY ended Mar/13 | FY ended Mar/12 | FY ended Mar/11 | FY ended Mar/10 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 514,048 | 253,350 | 577,458 | 624,808 | 638,329 | 624,245 |
| 89\% | 80\% | 92\% | 98\% | 102\% | 96\% |
| 33,163 | 13,551 | 34,350 | 35,555 | 32,269 | 30,313 |
| 97\% | 73\% | 97\% | 110\% | 106\% | 123\% |
| 231,143 | 115,665 | 194,846 | 177,977 | 174,836 | 159,795 |
| 119\% | 126\% | 109\% | 102\% | 109\% | 106\% |
| 24,999 | 13,508 | 22,105 | 21,585 | 21,226 | 21,734 |
| 113\% | 118\% | 102\% | 102\% | 98\% | 199\% |
| 139,287 | 68,078 | 117,483 | 114,084 | 113,556 | 105,437 |
| 119\% | 122\% | 103\% | 100\% | 108\% | 99\% |
| 4,282 | 2,750 | 9,285 | 8,888 | 7,551 | 5,875 |
| 46\% | 58\% | 104\% | 118\% | 129\% | 102\% |
| 106,853 | 49,990 | 95,178 | 90,338 | 88,491 | 93,187 |
| 112\% | 119\% | 105\% | 102\% | 95\% | 104\% |
| 102 | -289 | 5,491 | 6,554 | 8,327 | 6,112 |
| 2\% | -13\% | 84\% | 79\% | 136\% | - |
| 991,332 | 487,084 | 984,967 | 1,007,208 | 1,015,213 | 982,664 |
| 101\% | 96\% | 98\% | 99\% | 103\% | 98\% |
| 62,548 | 29,521 | 71,232 | 72,584 | 69,374 | 64,034 |
| 88\% | 80\% | 98\% | 105\% | 108\% | 157\% |

- Domestic Food Products: Previous years' figures for Kellogg's products
restated as net sales less cost of sales
- Medical foods: Moved from Pharmaceuticals to Other Business
(figures for previous years not restated).
Pharmaceuticals: Sales decreased due to transfer of Infusions and dialysis business in July 2013.


[^0]:    : from Pharmaceuticals to Other Business since FY ended Mar/14

